Multiple-dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in T2DM

Inclusion Criteria: * Age ≥18 and Age ≤70 years * T2DM patients, * Control the blood glucose level only with diet and exercise in last 3 months; * BMI ≥19 and BMI ≤ 35 kg/m2 (Body Mass Index) * HbA1c ≥7.0% and HbA1c \<10.0% * FPG \<13.9 mmol/L Exclusion Criteria: * Non-type 2 diabetes mellitus: Type 1 diabetes mellitus, gestational diabetes history; * History of acute complications of diabetes (diabetic ketoacidosis, diabetic hyperglycemia hyperosmolar syndrome or lactic acidosis); * History of chronic complications of severe diabetes (retinal proliferative disease, severe diabetic neuropathy or intermittent claudication confirmed by fundus examination during screening); * Patients who used systemic glucocorticoids within 3 months prior to screening had severe infections or major surgeries and transplants within 3 months; * Three or more episodes of hypoglycemia occurred in the six months prior to screening; * History of hyperthyroidism within 6 months before screening; * Severe cardiovascular disease. ; * Medical conditions that may significantly affect drug absorption, distribution, metabolism, and excretion within 2 weeks prior to screening; * Liver function tests abnormal; * Moderate or severe renal impairment; * Medical history or clinical evidence of pancreatic injury or pancreatitis, or abnormalities in lipase and amylase judged by investigators to be clinically significant; * Patients with a history of hypertension who regularly take antihypertensive therapy for over 4 weeks still have poor control, SBP \> 160 mmHg and (or) DBP \> 100 mmHg; * Patients with uncontrolled hyperlipidemia.